Quentin Anstee joins the Surfers (including Stephen Harrison) to share lessons about the proper use of non-invasive tests in the clinical trial process and to explore implications for best practices and future research or research.
Surfing the NASH Tsunami shares Dr. Mazen Noureddin’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD pathophysiology and NASH epidemiology. After this, he answers questions from Roger Green.
Jörn Schattenberg, Louise Campbell and Roger Green wrap up the discussion of NASH drug development in 2022 by citing their reasons for optimism, ranging from what researchers have proven already about safety and efficacy to the likelihood that combination therapy will eventually become the core therapeutic strategy and the emerging importance of quality of life measures.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green all discuss the role that combination NASH drugs and greater population diversity in clinical trials will strengthen NASH drug development.
Stephen Harrison discusses the state of NASH Drug Development in 2022 with focus on the key steps on the pathway and how late-stage NASH drugs are progressing
Stephen Harrison leads a review of drug development and where we are in the NASH pipeline as Jörn Schattenberg, Louise Campbell and Roger Green lend their own perspectives and ask questions
On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and online for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.)
Innovations in NAFLD Care conferece co-chair Jeff Lazarus joins Roger Green, Louise Campbell and Jörn Schattenberg to review conference goals and ask whether the agenda and participants put forth a vision of an integrated NAFLD Care pathway. This conversation centers around areas for controversy, including data-driven patient empowerment and what the proper name for this disease should be.
Co-chair Jeff Lazarus joins the Surfers (including co-chair Jörn Schattenberg) to review last week’s Innovations in NAFLD Care 2022 conference PLUS Roger Green interviews one of the events’ speakers, Human Edge CEO Dr. Marcus Ranney
Professor Ian Rowe and scientist/entrepreneur Rachel Zayas join the Surfers to preview the 5th Global NASH Congress. This conversation focuses on a range of topics.
